N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=83 Stroke Telemedicine Outpatient Prevention Program for Blood Pressure Reduction
Stroke Prevention · Blood Pressure · Telemedicine
Primary: Daytime Ambulatory Systolic Blood Pressure — 123.6; 128.3 millimeters of mercury (mmHg)
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
N/A N=140 Reducing Risk of Recurrence
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
N/A N=1,186 SDM for Stroke Prevention in Atrial Fibrillation
Atrial Fibrillation
Primary: Number of Clinician Satisfied Encounters — 277; 400 encounters
Phase 3 N=88 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants
Phase 4 N=246 DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Ventricular Tachycardia · Premature Ventricular Contraction · Stroke
Primary: Number of Participants With Transient Ischemic Attack — 6; 22 participants — p=0.001
N/A N=600 Prevent Return of Stroke Study
Stroke Recurrence · Transient Ischemic Attack
Primary: Blood Pressure — 76; 65 percentage of participants
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
Phase 4 N=20,332 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes
Stroke
Primary: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only) — 916; 898 Participants — p=0.7830
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=148 PRescriptiOn PattERns Of Oral Anticoagulants
Atrial Fibrillation
Primary: Number of Patients With at Least One Inappropriate MAI Criterion — 61; 11; 17 participants
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
Phase 4 N=2,716 Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
Cerebral Infarction
Primary: Numbers of Patients With First Occurence of Stroke — 82; 119 participants — p=0.0357
Phase 2 N=65 Argatroban Stroke Treatment - A Pilot Safety Study
Ischemic Stroke
Primary: Symptomatic and Radiographic Intracerebral Hemorrhage — 6.2 percentage of patients
Phase 2 N=13 Stroke Feasibility Study
Atrial Fibrillation · AFib
Primary: Number of Serious Adverse Events Within 30 Days Post-Index Procedure — 0 participants
N/A N=174 Adapting Tools to Implement Stroke Risk Management to Veterans
Ischemic Stroke · Transient Ischemic Attack
Primary: Stroke Specific Health Related Quality of Life — 3.80; 3.94; 2.98; 3.04 units on a scale — p=0.69
N/A N=3,000 PROTECTED TAVR: Stroke PROTECTion With SEntinel During Transcatheter Aortic Valve Replacement
Stroke
Primary: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) — 34; 43 Participants
Phase 3 N=18,201 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Atrial Fibrillation · Atrial Flutter
Primary: Number of Participants With First Event of Ischemic/Unspecified Stroke, Hemorrhagic Stroke, or Systemic Embolism (SE) During the Intended Treatment Period — 159; 173…
Phase 3 N=11,016 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
Phase 2 N=148 Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment
Atherosclerosis · Adherence, Medication · Tolerance
Primary: Carotid Intimal Media Thickness — -0.017; -0.092 mm
Phase 3 N=1,578 Japan Statin Treatment Against Recurrent Stroke (J-STARS)
Ischemic Stroke
Primary: Incidence Rate of Stroke and TIA — 2.56; 2.65 events /100 person-years — p=0.8234
N/A N=8,164 VITATOPS: A Study of VITAmins TO Prevent Stroke
Stroke · Transient Ischemic Attack
Primary: Non-fatal Stroke, Non-fatal Myocardial Infarction or Death Due to Vascular Causes — 616; 678 Participants — p=0.05
Phase 3 N=5,390 Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
Stroke · Secondary Prevention
Primary: Adjudicated Recurrent Stroke — 4.09; 4.80 Annualised event rate (%/ year) — p=0.1028
Phase 2 N=8 Poststroke Depression in Hemorrhagic Stroke
Stroke Hemorrhagic · Depression
Primary: Depression — 12.33; 6 units on a scale
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants